Impact of early vs. late disease onset on treatment response to etanercept in patients with psoriasis.
Dermatology Centre, Manchester Academic Health Science Centre, Salford Royal Hospital, University of Manchester, M6 8HD, Manchester, U.K. christopher.griffiths@manchester.ac.uk.
C E M
CE
Griffiths
University of Kiel, Kiel, Germany.
E
E
Christophers
Specialty Care, Pfizer Inc, Collegeville, PA, U.S.A.
A
A
Szumski
Specialty Care, Pfizer Inc, Collegeville, PA, U.S.A.
H
H
Jones
Specialty Care, Pfizer Inc, Collegeville, PA, U.S.A.
L
L
Mallbris
D000328:Adult; D017668:Age of Onset; D000368:Aged; D003879:Dermatologic Agents / Q000627:therapeutic use*; D000068800:Etanercept / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome
D003879:Dermatologic Agents; D000068800:Etanercept